| PHENAZOPYRIDINE HYDROCHLORIDE
Azo-Standard, Baridium, Geridium, Phenazo , Phenazodine, Pyridiate, Pyridium, Pyronium , Urodine, Urogesic
Classifications: urinary tract analgesic; Therapeutic: urinary tract analgesic
Pregnancy Category: B
95 mg, 97.2 mg, 100 mg, 150 mg, 200 mg tablets
Azo dye that has local anesthetic action on urinary tract mucosa, which imparts little or no antibacterial activity.
Effective as a urinary tract analgesic.
Symptomatic relief of pain, burning, frequency, and urgency arising from irritation of urinary tract mucosa, as from infection,
trauma, surgery, or instrumentation.
Renal insufficiency, glomerulonephritis, pyelonephritis, renal failure, uremia; hepatic disease; glucose-6-phosphate dehydrogenase
deficiency, severe hepatitis.
GI disturbances; older adults; pregnancy (category B), lactation.
Route & Dosage
Adult: PO 200 mg t.i.d.
Child: PO 12 mg/kg/d in 3 divided doses
- Give with or after meals.
Adverse Effects (≥1%)Body as a Whole:
Headache, vertigo. GI:
Mild GI disturbances. Urogenital:
Kidney stones, transient acute kidney failure. Metabolic:
Methemoglobinemia, hemolytic anemia
Skin pigmentation. Special Senses:
May stain soft contact lenses.
Diagnostic Test Interference
Phenazopyridine may interfere with any urinary test that is based on color reactions or spectrometry: bromsulphalein and phenolsulfonphthalein excretion tests; urinary glucose test using Clinistix or TesTape (copper-reduction methods such as Clinitest and Benedict's test reportedly not affected); bilirubin using "foam test" or Ictotest; ketones using nitroprusside (e.g., Acetest, Ketostix, or Gerhardt ferric chloride); urinary protein using Albustix, Albutest, or nitric acid ring test; urinary steroids; urobilinogen; assays for porphyrins.
No clinically significant interactions established.
Readily absorbed from GI tract. Distribution:
Crosses placenta in trace amounts. Metabolism:
In liver and other tissues. Elimination:
Primarily in urine.
Assessment & Drug Effects
- Lab tests: Obtain periodic blood work and kidney function tests in patients on prolonged therapy or with impaired kidney
Patient & Family Education
- Be aware that drug will impart an orange to red color to urine and may stain fabric.
- Discontinue drug report to physician immediately the appearance of yellowish tinge to skin or sclerae may indicate drug accumulation
due to renal impairment.
- Discontinue drug when pain and discomfort are relieved (usually 315 d). Keep physician informed.